ProCE Banner Activity


Targeting IL-13 in Moderate to Severe Atopic Dermatitis: Forging a New Path to Improved Disease and Patient Outcomes


Atopic dermatitis (AD) significantly impacts physical, social, and psychological well-being. Recently, novel, more effective treatment options have been approved, including those targeting interleukin (IL)-13. Watch this webcast for expert insights on incorporating these agents to optimize care for patients with moderate to severe AD.

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurse Practitioners: 1.00 Nursing contact hours, includes 1.00 hour of pharmacotherapy credit

Released: May 15, 2023

Expiration: May 14, 2024

No longer available for credit.



Terry Faleye

Terry Faleye, MPAS, PA-C

Dermatology Physician Assistant
DermSurgery Associates
Houston, Texas

Jonathan Silverberg

Jonathan Silverberg, MD, PhD, MPH

Director of Clinical Research
Director of Patch Testing
George Washington University School of Medicine and Health Sciences
Washington, DC

Provided by

ProCE Banner


This activity is supported by an educational grant from Lilly.


Target Audience

This program is primarily intended for NPs and PAs who practice in dermatology.

Program Learning Goal

The goal of this program is to improve learners’ knowledge, competence, and performance regarding the targeted mechanism of action of IL-13 therapy for moderate to severe AD and their potential impact on disease and patient outcomes.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Recognize the burden of AD and its impact on patients

  • Detail the targeted mechanism of action of IL-13 therapy in moderate to severe AD and its potential impact on disease and patient outcomes

  • Incorporate patient-specific preferences and goals into treatment clinical decision-making discussions


Partners for Advancing Clinical Education (PACE) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity.

Jonathan I. Silverberg, MD, PHD, MPH: consultant/advisor: AbbVie, Aobiome, Arcutis, Amgen, Arena, Asana, Aslan, BioMX, Biosion, Bodewell, Boehringer Ingelheim, Cara, Castle Biosciences, Celgene, Connect Biopharma, Dermavant, Dermira, Dermtech, Galderma, GlaxoSmithKline, Incyte, Kiniksa, Leo, Lilly, Menlo, Novartis, Optum, Pfizer, RAPT, Regeneron, Sanofi, Shaperon, Union.

Terry Faleye, MPAS, PA-C, consultant/advisor/speaker: AbbVie, Bristol Myers Squibb, Eli Lilly, EPI Health, Leo Pharma, Novartis, Regeneron, Sun Pharma.

The planners and content peer reviewers from Partners for Advancing Clinical Education and Practicing Clinicians Exchange do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 15, 2023, through May 14, 2024: 

1. Login or Sign Up for an account by clicking at the top of this page.

2. Read the target audience, learning objectives, and faculty disclosures.

3. View and study the content in its entirety.

4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement

In support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

ANCC Credit Designation

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour, including 1.0 hour of pharmacology credit.

AAPA Credit Designation

LogoDescription automatically generated

Partners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until May 14, 2024. PAs should only claim credit commensurate with the extent of their participation.

IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.